Skip to main content

Advertisement

SpringerLink
Log in

Five-day 4′-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia

  • Original Papers
  • Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

Twenty-two patients with acute myeloid leukemia (AML), having a median age of 48.3 years (range 26–70; 10 male, 12 female), were treated with 4′-(9-acridinylamino)methanesulphon-m-anisidide (m-AMSA) 100 mg/m2 and cytosine arabinoside (AraC) 2×1000 mg/m2 i.v. on days 1–5. There were 2 M1, 8 M2, 9 M4, 2 M4 Eo, and 1 M5a. Of these, 12 achieved a complete remission, 3 a partial remission and 6 did not respond. The median remission duration was 9.0 months and the median overall survival 8.1 months. Side-effects of induction consisted mainly of haematological toxicity and infections with a median duration of WHO-grade-4 granulopenia and thrombopenia of 20 and 28 days respectively. Organ toxicity was mild with mucositis and cutaneous and liver toxicity being experienced by only a few patients. There was one treatment-related death. Five-day m-AMSA and intermediate-dose AraC is an easy-to-handle condensed treatment schedule with tolerable toxicity. Its effectiveness in relapsed and refractory AML is comparable to combinations of high-dose AraC with m-AMSA, anthracyclines or etoposide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AraC:

cytosine arabinoside

m-AMSA:

4′-(9-acridinylamino)methanesulphon-m-anisidide

References

  • Amadori S, Papa G, Miniero R, Meloni G, Petti MC, Mandelli F (1988) Intermediate-dose ara-C (IdAC) with sequential mitoxantrone (Mitox) in acute myeloid leukemia (AML) (abstract). Proc Am Soc Clin Oncol 7:A670

    Google Scholar 

  • Arlin ZA, Ahmed T, Mittelman A, Feldman E, Mehta R, Weinstein P, Rieber E, Sullivan P, Baskind P (1987) A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. J Clin Oncol 5:371–375

    Google Scholar 

  • Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnik HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British cooperative group. Ann Intern Med 103:626–629

    Google Scholar 

  • Berman E, Arlin ZA, Gaynor J, Miller W, Gee T, Kempin SJ, Mertelsmann R, Andreeff M, Reich L, Nahmias N, et al. (1989) Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia 3:115–121

    Google Scholar 

  • Breithaupt H, Pralle H, Eckhardt T, von Hattingberg M, Schick J, Loeffler H (1982) Clinical results and pharmacokinetics of high dose cytosine arabinoside (HD ARA-C). Cancer 50:1248–1257

    Google Scholar 

  • Brito-Babapulle F, Catovsky D, Newland AC, Goldman JM, Galton DAG (1987) Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone. Semin Oncol 14 [Suppl 1]:51–52

    Google Scholar 

  • Cheng PN, Leung TW, Shiu WC (1987) Etoposide, high dose ara-C and asparaginase in poor risk acute myeloid leukaemias in Hong Kong (abstract). EORTC Symposium on Recent Advances in Cancer Management 14–15

  • Decker RW, Ho WG, Champlin RE (1987) Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia. Cancer Treat Rep 71:881–882

    Google Scholar 

  • Dupont J, Garay G, Scaglione C, Wooley P, Pavlovski S (1981) A phase II trial of m-AMSA in acute leukemia (abstract). Proc Am Assoc Cancer Res Am Soc Clin Oncol 22:477

    Google Scholar 

  • Early AP, Preisler HD, Slocum H, Rustum YM (1982) A pilot study of high-dose 1-Β-d-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 42:1587–1594

    Google Scholar 

  • French-American-British (FAB) Co-Operative Group, Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. Br J Haematol 33:489–496

    Google Scholar 

  • Gore M, Powles R, Lakhani A, Milan S, Maitland J, Goss G, Nandi A, Perren T, Forgeson G, Treleaven J, Zuiable A, Porta F (1989) Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide. Cancer Chemother Pharmacol 23:373–376

    Google Scholar 

  • Gryn J, Conroy J, Crilly P, Topolsky D, Kahn SB, Brodsky I (1989) High-dose cytarabine (HDAC) and VP-16 for refractory or relapsed ANLL (abstract). Proc Am Soc Clin Oncol 8:202

    Google Scholar 

  • Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62:361–369

    Google Scholar 

  • Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69:744–749

    Google Scholar 

  • Hiddemann W, Maschmeier G, Pfreundschuh M, Ludwig WD, Büchner Th (1988) Treatment of refractory acute myeloid (AML) and lymphoblastic leukemia (ALL) with high-dose cytosine arabinoside (Hd Ara-C) and mitoxantrone: indication of increased efficacy by sequential administration (abstract). Proc Am Sco Clin Oncol 7:A731

    Google Scholar 

  • Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick HJ (1984) High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute non lymphocytic leukemia. J Clin Oncol 2:545

    Google Scholar 

  • Issell BF (1980) Amsacrine. Cancer Treat Rev 7:73–83

    Google Scholar 

  • Jehn U, Heinemann V (1990) Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia. Hamatol Bluttransfus 33:333–338

    Google Scholar 

  • Kantarjian HM, Estey EH, Plunkett W, Keating M, Walters RS, Iacoboni S, McCredie KB, Freireich EJ (1986) Phase I–II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81:387–391

    Google Scholar 

  • Kaplan EL, Meyer P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457–457

    Google Scholar 

  • Keating MJ, Gehan EA, Smith TL, Estey EH, Walters RS, Kantarjian HM, McCredie KB, Freireich EJ (1987) A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol 5:710–721

    Google Scholar 

  • Lawrence HJ, Ries CA, Reynolds RD, Levis JP, Kroetz MM, Torti FM (1982) AMSA — a promising new agent in refractory acute leukemia. Cancer Treat Rep 66:1475–1478

    Google Scholar 

  • Legha SS, Keating MJ, Zander AR, McCredie KB, Bodey GP, Freireich FJ (1980) 4′(9-acridinylamino) methanesulfon-m-anisidide: a new drug effective in the treatment of adult acute leukemia. Ann Intern Med 93:17–21

    Google Scholar 

  • Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Google Scholar 

  • Ohnuma T, Rosner S, Levy RN, Cuttner Jetal, Moon JH, Silver RT, Blom J, Falkson G, Burningham R, Glidewell O, Holland JF (1971) Treatment of adult leukemia withl-asparaginase. Cancer Chemother Rep 55:269–275

    Google Scholar 

  • Peters WG, Willemze R, Colly LP (1988) Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia. Eur J Haematol 40:198–204

    Google Scholar 

  • Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ (1987a) Saturation of 1-Β-d-arabinofura-nosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-Β-d-arabinofuranosylcytosine therapy. Cancer Res 47:3005–3011

    Google Scholar 

  • Plunkett W, Nowak B, Keating MJ (1987b) Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rep 71:479–483

    Google Scholar 

  • Rohatiner A, Slevin ML, Dhaliwal HS, Malpas JS, Lister TA (1984) High-dose cytosine arabinoside: response to therapy in acute leukemia and non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 12:90–93

    Google Scholar 

  • Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S (1979) High dose cytosine arabinoside in refractory acute leukemia. Cancer 44:1189–1193

    Google Scholar 

  • Sanz MA, Martinez J, Borrego D, Martin-Aragonés G, Lorenzo I, Sanz G, Sayas MJ, Jarque I, Pastor E, Rafecas J (1987) High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia. Semin Oncol 14 [Suppl 1]:18–20

    Google Scholar 

  • Slevin ML, Shannon MS, Prentice HG, Goldman AJ, Lister TA (1981) A phase I and II study of m-AMSA in acute leukemia. Cancer Chemother Pharmacol 6:137–140

    Google Scholar 

  • Takaku F, Urabe A, Mizoguchi H, Yamada O, Wakabayashi Y, Miura Y, Sakamoto S, Yoshida M, Miwa S, Asano S, Morisaka T, Nomura T, Toyama K, Aoki I, Murase T, Maekawa T, Miyawaki S, Murakami H, Yamada H, Ohno R, Kawashima K, Yokomaku S, Kinogasa K, Adachi Y, Mori M, Ise T, Mutoh Y, Yamaguchi H (1985) High-dose cytosine arabinoside in refractory acute leukemia. Semin Oncol 12 [Suppl 3]:144–150

    Google Scholar 

  • Tan CTC, Hancock C, Steinherz PG, Sorell M, Chan KW, Mondora A, Miller DR (1982) Phase II study of 4′(9-acridinylamino)-methanesulfon-m-anisidide (NSC-249992) in children with acute leukemia and lymphoma. Cancer Res 42:1579–1581

    Google Scholar 

  • Van Echo DA, Markus SD, Schimpff SC, Wiernik PH (1981) A phase II trial of 4′(9-acridinylamino-methanesulfon-m-anisidide in adult relapsed acute leukemia (abstract). Proc Am Assoc Cancer Res Am Soc Clin Oncol 22:230

    Google Scholar 

  • Van Prooyen HC, Dekker AW, Punt K (1984) The use of intermediate dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemia in relapse. Br J Haematol 57:291–299

    Google Scholar 

  • Vogler WR, Preisler HD, Winton EF, Gottlieb AJ, Goldberg J, Brennan J, Grunwald H, Rai K, Bowman G, Miller KB, Chervenick P, Azarnia N (1986) Randomized trial of high-dose cytosine arabinoside versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup study. Cancer Treat Rep 70:455–459

    Google Scholar 

  • Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ (1988) Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 62:677–682

    Google Scholar 

  • Willemze R, Fibbe WE, Zwaan FE (1983) Experience with intermediate and high dose cytosine arabinoside in refractory acute leukemia. Onkologie 4:200–204

    Google Scholar 

  • Willemze R, Jager U, Jehn U, Stryckmans P, Bury J, Suciu S, Solbu G, Zittoun R, Burghouts J, Loewenberg B, Abels J, Cauchie Ch (1988) Intermediate and high dose ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study. Eur J Cancer Clin Oncol 24:1721–1725

    Google Scholar 

  • Winton EF, Volger WR, Rose KL (1980) Phase II study of acrinidyl anisidide (NSC-249992) in refractory adult acute leukemia (abstract). Proc Am Assoc Cancer Res Am Soc Clin Oncol 21:437

    Google Scholar 

  • Witz F, Olive D, Lederlin P, Bordigoni P, Troussard X, Grosbois B, Schaison G, Cornu G (1987) IntérÊt des hautes doses de cytosine-arabinoside dans le traitement des leukcémies aiguËs résistantes. Presse Med 16:159–162

    Google Scholar 

  • Zittoun R, Bury J, Strykmans P, Löwenberg B, Peetermens M, Rozendaal KY, Haanen C, Kerkhofs M, Jehn U, Willemze R (1985) Amsacrine with high-dose cytarabine in acute leukemia. Cancer Treat Rep 69:1447–1448

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology and Oncology, Hannover Medical School, Federal Republic of Germany

    Mathias Freund, Simone Giller, Johannes Meran, Alfred Körfer, H. Link & Hubert Poliwoda

  2. Evangelisches Krankenhaus Oldenburg, Federal Republic of Germany

    Fokke Hinrichs & Axel Baars

Authors
  1. Mathias Freund
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simone Giller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fokke Hinrichs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Axel Baars
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Johannes Meran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alfred Körfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Link
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hubert Poliwoda
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freund, M., Giller, S., Hinrichs, F. et al. Five-day 4′-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 117, 489–492 (1991). https://doi.org/10.1007/BF01612772

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01612772

Key words

Search

Navigation